Skip to main content
Premium Trial:

Request an Annual Quote

MD Anderson, Guardant Health Partner to Push Liquid Biopsy into Cancer Clinic

NEW YORK (GenomeWeb) – The University of Texas MD Anderson Cancer Center and Guardant Health said today that they are entering a multi-year partnership that they hope will help accelerate the translation of Guardant's liquid biopsy technology into a standard-of-care tool for guiding the treatment of cancer patients.

Under the terms of the partnership, Guardant will help MD Anderson build multiple on-site liquid biopsy centers in which the center will develop new assays using Guardant's cell-free DNA-sequencing technology.

Guardant and MD Anderson will also jointly fund interventional clinical utility studies to demonstrate how this non-invasive targeted sequencing approach can improve patient outcomes across multiple types and stages of cancer. The research will be designed to support the incorporation of Guardant's test technology into national guidelines and its broad adoption as a standard-of-care tool.

Guardant360 will also become MD Anderson's preferred Liquid biopsy test, and the center's physicians will be able to order it directly through an electronic medical record system, Guardant added.

"While we have seen unprecedented uptake of Guardant360 since its launch as the world's first comprehensive liquid biopsy, we realize we are only scratching the surface of its potential impact on oncology," Guardant CEO Helmy Eltoukhy said in a statement.

According to MD Anderson President Ronald DePinho, the partnership will also contribute to ongoing efforts in the center's Moon Shots Program, which aims to reduce cancer deaths by accelerating the development and implementation of new diagnostics and treatments, particularly tools for prevention and early detection.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.